News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
768,683 Results
Type
Article (54346)
Company Profile (405)
Press Release (713918)
Multimedia
Podcasts (144)
Webinars (19)
Section
Business (214430)
Career Advice (2242)
Deals (37924)
Drug Delivery (134)
Drug Development (86015)
Employer Resources (178)
FDA (17260)
Job Trends (15784)
News (365219)
Policy (35134)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2827)
Academic (1)
Accelerated approval (37)
Adcomms (31)
Allergies (154)
Alliances (52908)
ALS (183)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (358)
Approvals (17494)
Artificial intelligence (605)
Autoimmune disease (176)
Automation (44)
Bankruptcy (383)
Best Places to Work (11957)
BIOSECURE Act (22)
Biosimilars (208)
Biotechnology (256)
Bladder cancer (166)
Brain cancer (64)
Breast cancer (675)
Cancer (5167)
Cardiovascular disease (434)
Career advice (1901)
Career pathing (39)
CAR-T (314)
CDC (57)
Celiac Disease (2)
Cell therapy (852)
Cervical cancer (38)
Clinical research (73001)
Collaboration (1860)
Company closure (4)
Compensation (1192)
Complete response letters (72)
COVID-19 (2895)
CRISPR (105)
C-suite (918)
Cystic fibrosis (151)
Data (6480)
Decentralized trials (2)
Denatured (41)
Depression (150)
Diabetes (521)
Diagnostics (6942)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (299)
Drug pricing (211)
Drug shortages (32)
Duchenne muscular dystrophy (243)
Earnings (92679)
Editorial (65)
Employer branding (21)
Employer resources (158)
Events (123164)
Executive appointments (1030)
FDA (20520)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1550)
Gene editing (219)
Generative AI (54)
Gene therapy (674)
GLP-1 (1066)
Government (4965)
Grass and pollen (7)
Guidances (385)
Healthcare (19553)
HIV (66)
Huntington's disease (50)
IgA nephropathy (88)
Immunology and inflammation (290)
Immuno-oncology (71)
Indications (123)
Infectious disease (3184)
Inflammatory bowel disease (211)
Inflation Reduction Act (15)
Influenza (124)
Intellectual property (262)
Interviews (360)
IPO (17132)
IRA (58)
Job creations (4180)
Job search strategy (1583)
JPM (66)
Kidney cancer (18)
Labor market (86)
Layoffs (618)
Leadership (36)
Legal (8683)
Liver cancer (98)
Longevity (16)
Lung cancer (705)
Lymphoma (393)
Machine learning (44)
Management (62)
Manufacturing (880)
MASH (174)
Medical device (14132)
Medtech (14193)
Mergers & acquisitions (21883)
Metabolic disorders (1366)
Multiple sclerosis (170)
NASH (17)
Neurodegenerative disease (348)
Neuropsychiatric disorders (100)
Neuroscience (3088)
Neurotech (1)
NextGen: Class of 2026 (6892)
Non-profit (4695)
Now hiring (68)
Obesity (653)
Opinion (312)
Ovarian cancer (170)
Pain (221)
Pancreatic cancer (243)
Parkinson's disease (297)
Partnered (34)
Patents (533)
Patient recruitment (515)
Peanut (62)
People (61958)
Pharmaceutical (100)
Pharmacy benefit managers (33)
Phase 1 (22806)
Phase 2 (32046)
Phase 3 (23954)
Pipeline (5665)
Policy (319)
Postmarket research (2747)
Preclinical (9961)
Press Release (71)
Prostate cancer (257)
Psychedelics (56)
Radiopharmaceuticals (305)
Rare diseases (940)
Real estate (6456)
Recruiting (73)
Regulatory (26236)
Reports (54)
Research institute (2601)
Resumes & cover letters (381)
Rett syndrome (28)
RNA editing (18)
RSV (84)
Schizophrenia (163)
Series A (264)
Series B (197)
Service/supplier (12)
Sickle cell disease (109)
Special edition (27)
Spinal muscular atrophy (168)
Sponsored (44)
Startups (3902)
State (2)
Stomach cancer (21)
Supply chain (110)
Tariffs (98)
The Weekly (100)
Vaccines (1096)
Venture capital (93)
Weight loss (434)
Women's health (99)
Worklife (18)
Date
Today (167)
Last 7 days (740)
Last 30 days (2624)
Last 365 days (31436)
2026 (4481)
2025 (31814)
2024 (36739)
2023 (41345)
2022 (52649)
2021 (57214)
2020 (55694)
2019 (48521)
2018 (36740)
2017 (34167)
2016 (33858)
2015 (39827)
2014 (33710)
2013 (29300)
2012 (31305)
2011 (31767)
2010 (29915)
Location
Africa (861)
Alabama (85)
Alaska (7)
Arizona (323)
Arkansas (15)
Asia (44302)
Australia (7356)
California (11683)
Canada (3370)
China (1178)
Colorado (496)
Connecticut (494)
Delaware (349)
Europe (96552)
Florida (1746)
Georgia (366)
Hawaii (3)
Idaho (65)
Illinois (907)
India (73)
Indiana (545)
Iowa (23)
Japan (449)
Kansas (131)
Kentucky (42)
Louisiana (28)
Maine (84)
Maryland (1439)
Massachusetts (8519)
Michigan (336)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (33)
Nebraska (29)
Nevada (126)
New Hampshire (84)
New Jersey (3101)
New Mexico (31)
New York (3103)
North Carolina (1534)
North Dakota (10)
Northern California (5696)
Ohio (347)
Oklahoma (22)
Oregon (47)
Pennsylvania (2358)
Puerto Rico (25)
Rhode Island (48)
South America (1260)
South Carolina (69)
South Dakota (1)
Southern California (4537)
Tennessee (180)
Texas (1810)
United States (41696)
Utah (351)
Vermont (1)
Virginia (286)
Washington D.C. (83)
Washington State (957)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
768,683 Results for "cell pathways inc acquired by osi pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lilly to acquire Orna Therapeutics to advance cell therapies
February 9, 2026
·
5 min read
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Press Releases
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
February 11, 2026
·
3 min read
Press Releases
Aviva Bio Announces FDA Guidance on Development Pathway for Women’s Testosterone Therapy and New Evidence of a Reduced Risk of Breast Cancer Cell Proliferation for AVA-291
January 27, 2026
·
4 min read
Gene therapy
In Vivo Is Having a Moment as Cell and Gene Therapy Sector Gathers in San Diego
A recurring theme Tuesday morning at Phacilitate’s Advanced Therapies Week was the quickly emerging potential of in vivo approaches to cell and gene therapy—a trend also reflected in recent investments by Eli Lilly and Regeneron.
February 11, 2026
·
4 min read
·
Heather McKenzie
Press Releases
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
February 12, 2026
·
6 min read
Sickle cell disease
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
February 23, 2026
·
6 min read
·
Heather McKenzie
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
The framework, first introduced by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research head Vinay Prasad in November, was criticized for lacking detailed guidance. Agency leaders elucidated on the pathway for personalized medicines on Monday.
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Manufacturing
J&J Plans $1B Investment in PA Cell Therapy Manufacturing Facility
Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.
February 19, 2026
·
2 min read
·
Nick Paul Taylor
1 of 76,869
Next
